MoonLake Immunotherapeutics (MLTX) Securities Class Action Lawsuit

Shamis & Gentile, P.A. alerts investors of the upcoming lead plaintiff deadline of December 15, 2025, in the securities class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake Immunotherapeutics” or the “Company”) (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025 (the “Class Period”).

The class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives misled investors about the clinical advantages of its only drug candidate, sonelokimab, and the benefits of its Nanobody structure. According to the complaint, the Company promoted sonelokimab as a superior therapy capable of greater tissue penetration and higher efficacy than traditional monoclonal antibodies. These claims, made during investor events starting on March 10, 2024, and reiterated in a November 7, 2024, press release, allegedly concealed that sonelokimab and its competitor BIMZELX target the same cytokines, IL-17A and IL-17F, and offered no proven clinical advantage.

The complaint contends the truth emerged on September 28, 2025, when MoonLake announced Phase 3 results showing that only one of two trials achieved statistical significance and that the drug failed to demonstrate competitive efficacy. The next trading day, September 29, 2025, the Company’s stock fell $55.75 per share, closing at $6.24 per share after an approximately 90% decline.

Investors who suffered significant losses from the purchase MoonLake Immunotherapeutics (MLTX) securities during the Class Period may have important legal rights and are encouraged to act promptly. The deadline to seek appointment as lead plaintiff is December 15, 2025.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.